{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:39:09Z","timestamp":1791844749186,"version":"4.3.4"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jiph.2025.103015","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:00:11Z","timestamp":1760695211000},"page":"103015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt"],"prefix":"10.1016","volume":"19","author":[{"given":"Atteyat A.","family":"Semeya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat S.A.","family":"Abdel Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa F.","family":"Al-Mihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Elgamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-0035","authenticated-orcid":false,"given":"Amira A.A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2025.103015_bib1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/jcp.27114","article-title":"Global estimate of gastric cancer in helicobacter pylori\u2013infected population: a systematic review and meta-analysis","volume":"234","author":"Pormohammad","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jiph.2025.103015_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12879-023-08504-5","article-title":"The global prevalence of gastric cancer in helicobacter pylori-infected individuals: a systematic review and meta-analysis","volume":"23","author":"Shirani","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/medicina57080803","article-title":"Impact of different helicobacter pylori eradication therapies on gastrointestinal symptoms","volume":"57","author":"Mestrovic","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.jiph.2025.103015_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The toronto consensus for the treatment of helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jiph.2025.103015_bib6","first-page":"1215","article-title":"Emphasizing the importance of successful eradication of helicobacter pylori on initial treatment","volume":"12","author":"Zhong","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jiph.2025.103015_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1756284821989177","article-title":"The status and progress of first-line treatment against helicobacter pylori infection: a review","volume":"14","author":"Liu","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000500819","article-title":"Current status of helicobacter pylori diagnosis and eradication therapy in Japan using a nationwide database","volume":"101","author":"Deguchi","year":"2020","journal-title":"Digestion"},{"key":"10.1016\/j.jiph.2025.103015_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819858511","article-title":"Current status of first-and second-line helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients","volume":"12","author":"Mori","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12876-017-0579-8","article-title":"Triple therapy versus sequential therapy for the first-line helicobacter pylori eradication","volume":"17","author":"Chang","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib11","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.3390\/molecules20046068","article-title":"Appropriate first-line regimens to combat helicobacter pylori antibiotic resistance: an asian perspective","volume":"20","author":"Miftahussurur","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.jiph.2025.103015_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13099-019-0305-x","article-title":"High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in helicobacter pylori isolated from karnataka patients","volume":"11","author":"Shetty","year":"2019","journal-title":"Gut Pathog"},{"key":"10.1016\/j.jiph.2025.103015_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of helicobacter pylori infection-the maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jiph.2025.103015_bib14","first-page":"52","article-title":"Comparison of three different regimens against helicobacter pylori as a first-line treatment: a randomized clinical trial","volume":"16","author":"Kefeli","year":"2016","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.jiph.2025.103015_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4166\/kjg.2024.012","article-title":"Comparison of the efficacy of 12-day concomitant quadruple therapy versus 14-day High-dose dual therapy as a First-line H. Pylori eradication regimen","volume":"83","author":"Toosi","year":"2024","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future developments","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jiph.2025.103015_bib17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/pathogens10070875","article-title":"Impact of dietary patterns on H. Pylori infection and the modulation of microbiota to counteract its effect. A narrative review","volume":"10","author":"Rueda-Robles","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.jiph.2025.103015_bib18","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","article-title":"Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for helicobacter pylori eradication: a phase III, randomised, double-blind study","volume":"65","author":"Murakami","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jiph.2025.103015_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1756283X16668093","article-title":"Vonoprazan-based therapy for helicobacter pylori eradication: experience and clinical evidence","volume":"9","author":"Akazawa","year":"2016","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib20","first-page":"1287","article-title":"Helicobacter pylori antibiotic resistance patterns among Egyptian children and predictors of resistance","volume":"4","author":"Abdallah","year":"2023","journal-title":"Microbes Infect Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib21","unstructured":"Egyptian Drug Authority. Gastropexy 20 mg Film-Coated Tablets. Issue no\/Rev no: 1\/1. Issue Date: 15\/08\/2023. Rev Date: 12\/12\/2023. \u3008https:\/\/www.edaegypt.gov.eg\/media\/eizjlloa\/par-gastropexy-20mg-tab.pdf\u3009."},{"key":"10.1016\/j.jiph.2025.103015_bib22","first-page":"135","article-title":"Vonoprazan a novel potassium competitive acid blocker; another leap forward","volume":"19","author":"Elsabaawy","year":"2024","journal-title":"Prz Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib23","first-page":"317","article-title":"Efficacy and safety of vonoprazan as a component of the first-and second-line eradication regimens for helicobacter pylori: a real-life Egyptian study","volume":"10","author":"Hanno","year":"2024","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.jiph.2025.103015_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.21608\/jesp.2024.373534","article-title":"Vonoprazan versus proton pump inhibitors in combination with antibiotics as a triple therapy for eradication of Clarithromycin-Resistant strain of helicobacter pylori","volume":"54","author":"Elfors","year":"2024","journal-title":"J Egypt Soc Parasitol"},{"key":"10.1016\/j.jiph.2025.103015_bib25","first-page":"131","article-title":"Efficacy of Potassium-competitive acid blockers versus proton pump inhibitors in First-and Second-line eradication regimens for helicobacter pylori in Egyptian patients","volume":"2","author":"Elazazi","year":"2024","journal-title":"J Transl Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib26","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s10620-017-4664-1","article-title":"Efficacy of vonoprazan-based triple therapy for helicobacter pylori eradication: a multicenter study and a review of the literature","volume":"62","author":"Tanabe","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jiph.2025.103015_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.970630","article-title":"Antibiotic resistance of helicobacter pylori isolated from patients in nanjing, China: a cross-section study from 2018 to 2021","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2025.103015_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS\u2014a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.jiph.2025.103015_bib29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on \u2018KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.jiph.2025.103015_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0016-5107(94)70067-2","article-title":"Comparison of biopsy sites for the histopathologic diagnosis of helicobacter pylori: a topographic study of H. Pylori density and distribution","volume":"40","author":"Genta","year":"1994","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jiph.2025.103015_bib31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis: the updated Sydney system","volume":"20","author":"Dixon","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jiph.2025.103015_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s004280000330","article-title":"Gastric polyps: an update of their pathology and biological significance","volume":"437","author":"Oberhuber","year":"2000","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jiph.2025.103015_bib33","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.20546\/ijcmas.2017.605.278","article-title":"Prevalence of helicobacter pylori antibodies in Egyptians with idiopathic thrombocytopenic purpura and in the general Egyptian population: a comparative study","volume":"6","author":"Hanafi","year":"2017","journal-title":"Int J Curr Microbiol Appl Sci"},{"key":"10.1016\/j.jiph.2025.103015_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s42506-019-0017-6","article-title":"Helicobacter pylori among symptomatic Egyptian children: prevalence, risk factors, and effect on growth","volume":"94","author":"Galal","year":"2019","journal-title":"J Egypt Public Health Assoc"},{"key":"10.1016\/j.jiph.2025.103015_bib35","first-page":"OC05","article-title":"Demographic, clinical, and endoscopic characteristics of active and Antibiotic-resistant H. Pylori-associated gastritis in Egyptian adults","volume":"12","author":"Wadea","year":"2018","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jiph.2025.103015_bib36","first-page":"1323","article-title":"Diabetes mellitus and hypertension are common comorbidities among COVID-19 hospitalized patients in Egypt: a single-center retrospective study","volume":"34","author":"Askar","year":"2021","journal-title":"Menou Med J"},{"key":"10.1016\/j.jiph.2025.103015_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/qjmed\/hcaa063.021","article-title":"Helicobacter pylori antibiotic resistance patterns among Egyptian children and predictors of resistance","volume":"113","author":"Awad","year":"2020","journal-title":"QJM"},{"key":"10.1016\/j.jiph.2025.103015_bib38","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.3748\/wjg.v25.i25.3183","article-title":"Infections with helicobacter pylori and challenges encountered in Africa","volume":"25","author":"Smith","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12635","article-title":"Epidemiology of helicobacter pylori infection","volume":"24","author":"Leja","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.jiph.2025.103015_bib40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3748\/wjg.v26.i10.995","article-title":"Global whole family-based helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer","volume":"26","author":"Ding","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib41","article-title":"Birth cohort and age-specific trends in global helicobacter pylori seroprevalence: a scoping review","volume":"38","author":"Taylor","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"10.1016\/j.jiph.2025.103015_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2036.11.s1.5.x","article-title":"Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer","volume":"11","author":"Kuipers","year":"1997","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.jiph.2025.103015_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.jiph.2025.103015_bib44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5009\/gnl17356","article-title":"Atrophic gastritis increases the risk of gastric cancer in asymptomatic population in korea","volume":"11","author":"Cheung","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.jiph.2025.103015_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21608\/ejmm.2019.283348","article-title":"Endoscopic and microbiological findings of helicobacter pylori infection among dyspeptic patients in suez canal university hospital","volume":"28","author":"El-Ghannam","year":"2019","journal-title":"Egypt J Med Microbiol"},{"key":"10.1016\/j.jiph.2025.103015_bib46","first-page":"1018","article-title":"Role of upper GIT endoscopy and histopathology in diagnosis and follow up of chronic gastritis","volume":"29","author":"Tawfeek Ibrahim","year":"2023","journal-title":"Zagazig Univ Med J"},{"key":"10.1016\/j.jiph.2025.103015_bib47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line helicobacter pylori treatment: a multicenter randomized trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jiph.2025.103015_bib48","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.12998\/wjcc.v10.i19.6349","article-title":"Current guidelines for helicobacter pylori treatment in east Asia 2022: differences among China, Japan, and South Korea","volume":"10","author":"Cho","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jiph.2025.103015_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijregi.2021.11.006","article-title":"Endoscopic and histopathological findings in adult dyspeptic patients, and their association with helicobacter pylori infection in Dhaka, Bangladesh","volume":"2","author":"Tanni","year":"2022","journal-title":"IJID Reg"},{"key":"10.1016\/j.jiph.2025.103015_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.102656","article-title":"Assessment of helicobacter pylori infection in Lebanon: endoscopic and histopathological findings","author":"Hind","year":"2025","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jiph.2025.103015_bib51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12866-022-02613-y","article-title":"Antibiotic resistance patterns of helicobacter pylori strains isolated from the Tibet autonomous region, China","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jiph.2025.103015_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2024.151622","article-title":"Antibiotic resistance and virulence genes in helicobacter pylori strains isolated from children in shanghai, China (2019\u20132022)","volume":"315","author":"Li","year":"2024","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.jiph.2025.103015_bib53","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/antibiotics12121672","article-title":"Antibiotic resistance in helicobacter pylori isolates from northwestern and central Romania detected by Culture-Based and PCR-Based methods","volume":"12","author":"Costache","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2025.103015_bib54","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/s12916-024-03816-y","article-title":"Global prevalence of helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis","volume":"22","author":"Salahi-Niri","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jiph.2025.103015_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245168","article-title":"Anemia and its association with helicobacter pylori infection among adult dyspeptic patients attending wachemo university nigist eleni mohammad memorial referral hospital, southwest Ethiopia: a cross-sectional study","volume":"16","author":"Haile","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2025.103015_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jgh3.12843","article-title":"Management of helicobacter pylori infection","volume":"7","author":"Aumpan","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.jiph.2025.103015_bib57","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1084\/jem.20181152","article-title":"Eosinophils can more than kill","volume":"215","author":"Berek","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.jiph.2025.103015_bib58","first-page":"139","article-title":"Is there a role for helicobacter pylori infection in urological diseases?","volume":"5","author":"Almarhoun","year":"2008","journal-title":"Urol J"},{"key":"10.1016\/j.jiph.2025.103015_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17745776","article-title":"Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","volume":"11","author":"Sugano","year":"2018","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib60","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jiph.2025.103015_bib61","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","article-title":"Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases","volume":"63","author":"Yang","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jiph.2025.103015_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21608\/bjas.2024.275367.1353","article-title":"Quality of life among patients with helicobacter pylori infection","volume":"9","author":"Sewilam","year":"2024","journal-title":"Benha J Appl Sci"},{"key":"10.1016\/j.jiph.2025.103015_bib63","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41598-025-85628-5","article-title":"Safety and effectiveness of dual therapy for helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2025.103015_bib64","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/gutjnl-2021-324032","article-title":"Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community","volume":"70","author":"Megraud","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jiph.2025.103015_bib65","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3748\/wjg.v9.i5.1126","article-title":"Type 2 diabetes mellitus affects eradication rate of helicobacter pylori","volume":"9","author":"Sarg\u00fdn","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.183480","article-title":"Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?","volume":"20","author":"Chawla","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jiph.2025.103015_bib67","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s001250050669","article-title":"Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycemia","volume":"40","author":"Jaap","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.jiph.2025.103015_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/2050312119832093","article-title":"Helicobacter pylori eradication in patients with type 2 diabetes mellitus: multicenter prospective observational study","volume":"7","author":"Nam","year":"2019","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.jiph.2025.103015_bib69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjmed.2005.10.003","article-title":"Smoking increases the treatment failure for helicobacter pylori eradication","volume":"119","author":"Suzuki","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jiph.2025.103015_bib70","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.dld.2017.03.010","article-title":"Smoking increases the likelihood of helicobacter pylori treatment failure","volume":"49","author":"Itskoviz","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib71","first-page":"G1037","article-title":"Mechanism of aggravation of mucosal injury by intravenous nicotine in rat stomach","volume":"261","author":"Endoh","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jiph.2025.103015_bib72","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2147\/IJGM.S456865","article-title":"Eradication rate and factors influencing helicobacter pylori infection clearance using standard triple therapy at a single centre in jazan region, Saudi Arabia: a retrospective study","author":"Darraj","year":"2024","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.jiph.2025.103015_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102312","article-title":"The impact of secondhand smoke on failure of helicobacter pylori therapy is not inferior to that of smoking","volume":"48","author":"Wu","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib74","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000490889","article-title":"Smoking and drinking did not increase the failure of therapeutic helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin","volume":"99","author":"Takara","year":"2019","journal-title":"Digestion"},{"key":"10.1016\/j.jiph.2025.103015_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12860","article-title":"Impact of smoking on the eradication of helicobacter pylori","volume":"27","author":"Yu","year":"2022","journal-title":"Helicobacter"},{"key":"10.1016\/j.jiph.2025.103015_bib76","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3748\/wjg.v23.i4.668","article-title":"Comparative study: vonoprazan and proton pump inhibitors in helicobacter pylori eradication therapy","volume":"23","author":"Sakurai","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib77","article-title":"Association of hypertension with helicobacter pylori: a systematic review and meta-analysis","volume":"17","author":"Fang","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2025.103015_bib78","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12879-022-07718-3","article-title":"Relationship between active helicobacter pylori infection and risk factors of cardiovascular diseases, a cross-sectional hospital-based study in a sub-Saharan setting","volume":"22","author":"Tali","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231182545","article-title":"Association between helicobacter pylori seropositivity and hypertension among adults in Northern Sudan: a community-based case\u2013control study","volume":"51","author":"Hassan","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jiph.2025.103015_bib80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000524078","article-title":"Relationship between helicobacter pylori and incident hypertension as well as blood pressure: a systematic review and meta-analysis","volume":"41","author":"Yue","year":"2023","journal-title":"Dig Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib81","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1523-5378.2003.00180.x","article-title":"Eradication of helicobacter pylori infection improves blood pressure values in patients affected by hypertension","volume":"8","author":"Migneco","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.jiph.2025.103015_bib82","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3390\/microorganisms9112351","article-title":"Impact of helicobacter pylori-related metabolic syndrome parameters on arterial hypertension","volume":"9","author":"Kountouras","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.jiph.2025.103015_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189310","article-title":"Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite","volume":"12","author":"Jaworska","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jiph.2025.103015_bib84","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jiph.2025.103015_bib85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fcimb.2017.00381","article-title":"Alterations of the gut microbiome in hypertension","volume":"7","author":"Yan","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2025.103015_bib86","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40168-016-0222-x","article-title":"Gut microbiota dysbiosis contributes to the development of hypertension","volume":"5","author":"Li","year":"2017","journal-title":"Microbiome"},{"key":"10.1016\/j.jiph.2025.103015_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.543698","article-title":"Risk factors for intestinal barrier impairment in patients with essential hypertension","volume":"7","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jiph.2025.103015_bib88","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/j.2040-4603.2015.tb00651.x","article-title":"The gastrointestinal circulation: physiology and pathophysiology","volume":"5","author":"Granger","year":"2015","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jiph.2025.103015_bib89","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.jiph.2025.103015_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12571","article-title":"Gastric cancer prevention targeted on risk assessment: gastritis OLGA staging","volume":"24","author":"Rugge","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.jiph.2025.103015_bib91","doi-asserted-by":"crossref","first-page":"107","DOI":"10.37349\/edd.2024.00043","article-title":"Helicobacter pylori and gastric cancer: a critical approach to who really needs eradication","volume":"3","author":"Kouroumalis","year":"2024","journal-title":"Explor Dig Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib92","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.3748\/wjg.v27.i31.5152","article-title":"Helicobacter pylori eradication: exploring its impacts on the gastric mucosa","volume":"27","author":"Weng","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib93","first-page":"34","article-title":"Chronic atrophic gastritis: Don\u2019t miss these nutritional deficiencies","volume":"44","author":"Gluckman","year":"2020","journal-title":"Pr Gastroenterol"},{"key":"10.1016\/j.jiph.2025.103015_bib94","series-title":"Helicobacter pylori: Physiology and Genetics","article-title":"Adherence and colonization","author":"Testerman","year":"2001"},{"key":"10.1016\/j.jiph.2025.103015_bib95","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/IJN.S502833","article-title":"Localized drug delivery in different gastrointestinal cancers: navigating challenges and advancing nanotechnological solutions","volume":"20","author":"Hasan","year":"2025","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.jiph.2025.103015_bib96","first-page":"185","article-title":"Predictors of failure of helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial","volume":"22","author":"Fallone","year":"1999","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.jiph.2025.103015_bib97","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1365-2036.2001.01006.x","article-title":"Predictors of failure of helicobacter pylori eradication with the standard \u2018Maastricht triple therapy\u2019","volume":"15","author":"Perri","year":"2001","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.jiph.2025.103015_bib98","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s12879-019-4085-1","article-title":"Predictors of triple therapy treatment failure among H. Pylori-infected patients attending at a tertiary hospital in northwest Tanzania: a prospective study","volume":"19","author":"Jaka","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2025.103015_bib99","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/microorganisms12010006","article-title":"Independent risk factors predicting eradication failure of hybrid therapy for the First-Line treatment of helicobacter pylori infection","volume":"12","author":"Chen","year":"2023","journal-title":"Microorganisms"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125003648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125003648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:12:39Z","timestamp":1785856359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125003648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1876034125003648"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.103015","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.103015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103015"}}